PROCTER & GAMBLE HEALTH LIMITED

BSE: PGHL500126ISIN INE199A01012

Healthcare
Pharmaceuticals
BSE 1000

Share price

₹5,708.15-148.75 (-2.54%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹6,955.00
52W low: ₹4,699.70
Off 52W high: -17.93%
1M return: +7.67%
3M return: -11.62%
6M return: +7.01%
1Y return: -5.76%
20D avg volume: 529
50 DMA: ₹5,466.37
200 DMA: ₹5,582.15

Key ratios Standalone

Market cap: ₹9,475 Cr
Current price: ₹5,708.15
52W high / low: ₹6,955.00 / ₹4,699.70
Face value: ₹10.00
P/E: 24.94
P/B: 15.52
EPS (TTM): ₹228.83
Book value / share: ₹367.79
ROE: 62.22%
ROCE: 76.80%
Operating margin: 40.85%
Net margin: 29.15%
Debt / equity: 0.00
Net debt: ₹-177.24 Cr
Interest cover: 818.93
Dividend yield: 3.59%
Dividend / share (TTM): ₹205.00
Payout: 89.59%
Cash conversion cycle: 28.2 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	382.49	363.71	370.45	373.86	324.92	338.74	310.99	309.77	313.41	283.88	252.48	309.97
	3.89	3.88	4.00	4.36	4.95	4.03	3.11	3.96	3.28	2.13	2.27	5.18
	386.38	367.59	374.45	378.22	329.87	342.77	314.10	313.73	316.69	286.01	254.75	315.15
	236.33	270.27	241.24	269.40	210.85	253.96	235.57	192.04	205.29	242.99	192.03	215.43
	71.69	80.31	85.19	84.47	78.13	59.54	90.82	61.60	48.17	67.42	64.66	70.84
	31.44	24.56	22.31	13.32	10.64	24.31	13.72	13.28	20.16	18.51	11.13	8.40
	53.77	60.39	50.86	61.81	53.88	56.01	48.79	47.05	46.22	48.63	48.46	57.43
	0.13	0.14	0.21	0.10	0.12	0.12	0.13	0.15	0.15	0.20	0.15	0.19
	6.08	6.02	6.17	5.90	6.08	5.44	5.37	5.55	5.77	7.16	6.84	6.92
	70.78	107.50	91.13	91.77	82.37	98.40	82.56	63.56	65.10	107.83	62.72	60.50
	150.05	97.32	133.21	108.82	119.02	88.81	78.53	121.69	111.40	43.02	62.72	99.72
	0.00	31.80	0.00	0.00	0.00	0.00	—	—	—	-20.19	—	—
	150.05	129.12	133.21	108.82	119.02	88.81	78.53	121.69	111.40	22.83	62.72	99.72
	38.54	32.97	38.61	31.23	30.48	22.63	17.35	30.79	29.07	6.05	16.16	27.65
	111.51	96.15	94.60	77.59	88.54	66.18	61.18	90.90	82.33	16.78	46.56	72.07
	67.18	57.92	56.99	46.74	53.34	39.87	36.86	54.76	49.60	10.11	28.00	43.40
Key metrics
	156.26	135.28	139.59	114.82	125.22	94.37	84.03	127.39	117.32	30.19	69.71	106.83
	40.90%	37.20%	37.70%	30.70%	38.50%	27.90%	27.00%	41.10%	37.40%	10.60%	27.60%	34.50%
	29.20%	26.40%	25.50%	20.80%	27.20%	19.50%	19.70%	29.30%	26.30%	5.90%	18.40%	23.30%
	20.90%	—	22.80%	—	17.70%	—	13.60%	—	—	—	—	—
	17.70%	7.40%	19.10%	20.70%	3.70%	19.30%	23.20%	-0.10%	—	—	—	—
	25.90%	45.30%	54.60%	-14.60%	7.50%	294.40%	31.40%	26.10%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	1,491	1,408	934.17	1,151	1,230	1,114
	16.13	17.34	10.35	15.63	18.39	13.19
	1,507	1,425	944.52	1,167	1,248	1,128
	1,017	975.45	632.90	873.38	933.81	874.23
	321.66	307.33	200.59	290.23	319.23	323.72
	91.63	70.58	47.16	39.46	39.76	20.83
	226.83	222.56	142.06	215.16	206.17	167.56
	0.58	0.55	0.43	0.72	0.77	0.42
	24.17	23.59	16.69	27.40	27.37	27.81
	361.18	363.67	211.22	299.54	337.66	338.64
	489.40	449.86	311.62	293.51	314.20	253.37
	31.80	0.00	0.00	-20.19	—	—
	521.20	449.86	311.62	273.32	314.20	253.37
	141.35	122.95	77.21	72.34	84.73	60.85
	379.85	326.91	234.41	200.98	229.47	192.52
	228.83	196.94	141.22	121.07	138.23	116.00
Key metrics
	545.95	474.00	328.74	301.44	342.34	281.60
	36.63%	33.70%	35.20%	26.20%	27.80%	25.30%
	25.48%	23.20%	25.10%	17.50%	18.70%	17.30%
	—	76.80%	53.90%	—	—	—
	16.05%	50.70%	-18.90%	-6.40%	10.30%	—
	23.81%	39.50%	16.60%	-12.40%	19.20%	—
	—	322.28	168.69	—	—	—
	—	1.03	0.72	—	—	—
	—	0.00	0.00	—	—	—
	—	-177.24	-182.08	—	—	—
	—	28.2	32.5	—	—	—
Balance sheet
	—	841.35	794.20	—	—	—
	—	556.26	526.39	—	—	—
	—	177.24	182.08	—	—	—
	—	164.26	145.40	—	—	—
	—	136.65	109.37	—	—	—
	—	51.80	63.97	—	—	—
	—	99.24	104.63	—	—	—
	—	192.17	171.60	—	—	—
	—	254.93	215.31	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	0.00	0.00	—	—	—
	—	524.55	536.96	—	—	—
Cash flow
	—	337.79	168.69	—	—	—
	—	1.26	9.59	—	—	—
	—	-343.92	-234.74	—	—	—
	—	15.51	0.00	—	—	—

Compounded growth

Sales CAGR 3Y: +4.62%
Sales CAGR 5Y: —
Profit CAGR 3Y: +12.52%
Profit CAGR 5Y: —
Sales YoY (TTM): +16.05%
Profit YoY (TTM): +23.81%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 51.82%

Holder	Type	Holding	Previous	Change
PROCTER AND GAMBLE OVERSEAS INDIA B.V.	Promoter	51.82%	—	—
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA SMA	Public	4.18%	—	—
LIFE INSURANCE CORPORATION OF INDIA	Public	1.87%	—	—
UTI-MNC FUND	Public	1.45%	—	—
ADITYA BIRLA SUN LIFE MUTUAL FUND - ADITYA BIRLA S	Public	1.22%	—	—
Procter & Gamble Manufacturing GmbH	Promoter Group	0.00%	—	—
Procter & Gamble France S.A.S.	Promoter Group	0.00%	—	—
Ismail Abudawood and Procter and Gamble Limited	Promoter Group	0.00%	—	—
Celtic Insurance Company, Inc.	Promoter Group	0.00%	—	—
Procter & Gamble Business Services Canada Company	Promoter Group	0.00%	—	—
First Aid Beauty Limited	Promoter Group	0.00%	—	—
Gillette Australia Pty. Ltd.	Promoter Group	0.00%	—	—
Modern Products Company	Promoter Group	0.00%	—	—
Procter & Gamble Canada Holding B.V.	Promoter Group	0.00%	—	—
LLC with foreign investments Procter & Gamble Ukraine	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
PROCTER & GAMBLE HEALTH LIMITED S	9,475	5,708.15	24.94	76.80%	+16.05% TTM	+23.81% TTM	-5.76%

Filings & corporate actions

Recent announcements

Press release for the unaudited financial results for the quarter ended September 30, 2026.2 Nov 2026 · Company Update / Press Release / Media Release
Outcome of Board Meeting for the Quarter Ended September 30, 20262 Nov 2026 · Result / Financial Results
Outcome of the Board Meeting for the Quarter and half year ended September 30 , 2026.2 Nov 2026 · Board Meeting / Outcome of Board Meeting
Please find attached signed Certifiacte for confirming compliance under Regulation 74(5) of the SEBI (DP) Regulations, for the quarter ended September 30, 2026.7 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve unaudited financial ....30 Sep 2026 · Board Meeting / Board Meeting
We would like to inform you that the Trading Window of the Company shall remain closed for the Directors and Designated Employees from October 1, 2026 until 48 hours from the publication ....25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Stock Exchange is informed about an update on Ease of doing Investment - Special Window for Transfer and Dematerialization.18 Sep 2026 · Company Update / General
The shareholders at their AGM held on September 3, 2026 approved the re-appointment of Mr. S. Madhavan as Independent Director of the Company for a period of 5 years effective November 15, 2026.4 Sep 2026 · Company Update / General
Scrutinizers Report and E-Voting results for the Annual General Meeting held on September 3, 2026.4 Sep 2026 · AGM/EGM / AGM
Enclosed a summary of proceedings of the Annual General Meeting held today, viz., September 3, 2026.3 Sep 2026 · AGM/EGM / AGM
The 59th Annual General Meeting of the Company is scheduled on Thursday, September 3, 2026 at 2:30 PM.12 Aug 2026 · AGM/EGM / AGM
The BRSR Report for the Financial Year ended March 31, 2026 is enclosed.12 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report for the Financial Year 2025-26 is enclosed for the Annual General Meeting scheduled on Thursday September 3, 2026.12 Aug 2026 · Others / Reg. 34 (1) Annual Report
Enclosed herewith is the Annual Report for the Financial Year 2025-26 and Notice calling the 59th Annual General Meeting of the Company, scheduled on Thursday, September 3, 2026 at 2:30 p.m.12 Aug 2026 · AGM/EGM / AGM
Record Date for Purpose of Dividend10 Aug 2026 · Corp. Action / Record Date
Press Release on the Unaudited Financial Results for the Quarter ended June 30, 2026.6 Aug 2026 · Company Update / Press Release / Media Release
Unaudited Financial Results for the Quarter ended June 30, 20266 Aug 2026 · Result / Financial Results
Outcome of Board Meeting.6 Aug 2026 · Board Meeting / Outcome of Board Meeting
Dear Sir/Madam, Please find attached intimation regarding change in Company''s Annual General Meeting date for the Financial Year 2025-26 and record date for purpose of AGM/distribution ....15 Jul 2026 · Company Update / General
Dear Sir, Please find attached signed certificate for confirming compliance under Regulation 74 (5) of the SEBI (DP) Regulations, for the quarter ended June 30, 2026.3 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Dear Sir, Please find attached communication in respect of deduction of TDS on the amount of final dividend income from the Company, if approved by the shareholders at the ensuing AGM.26 Jun 2026 · Company Update / General
Dear Sir, Please find attached our intimation for closure of trading window.26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2026 ,inter alia, to consider and approve Dear Sir, In terms ....26 Jun 2026 · Board Meeting / Board Meeting
Pursuant to regulation 30 of the SEBI (LODR) Regulations, 2015, we hereby inform you regarding changes in the Senior Management Personnel of the Company shall take place effective July 1, 2026.25 Jun 2026 · Company Update / Change in Management
The Company has informed the Stock Exchange regarding the transcript and link to the recording of the analyst/institutional investors meeting held earlier today.18 Jun 2026 · Company Update / Analyst / Investor Meet
The Company has informed the Stock Exchange regarding the Presentation of the Analyst/Institutional investor meet scheduled to be held today.18 Jun 2026 · Company Update / Analyst / Investor Meet
We wish to inform you that the management of the Company will be hosting a virtual connect with analysts/ institutional investors on June 18th at 2.30 pm IST. Institutional investors/Analysts ....4 Jun 2026 · Company Update / Analyst / Investor Meet
Please find attached signed Annual Secretarial Compliance report for the year ended March 31, 202627 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Record date for purpose of dividend26 May 2026 · Corp. Action / Record Date
Board has recommended final dividend for the Financial Year 2025-26, subject to approval of shareholders.26 May 2026 · Corp. Action / Dividend
Please find attached press release for the quarter and financial year ended March 31, 2026.26 May 2026 · Company Update / Press Release / Media Release
Dear Sir, Please find attached intimation for re appointment of Independent Director.26 May 2026 · Company Update / Change in Management
Dear Sir, Please find attached audited financial results for the year ended March 31, 2026.26 May 2026 · Result / Financial Results
We are enclosing herewith the following: a. Audited Financial Results for the Financial Year ended March 31, 2026, as per format prescribed under Regulation 33 of Securities Exchange Board ....26 May 2026 · Board Meeting / Outcome of Board Meeting
Dear Sir, Please find attached our intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015. Request you to kindly take the same on record.30 Apr 2026 · Company Update / General
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....6 Apr 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Dear Sir/Madam, Please find attached disclosure under regulation 74(5) of the SEBI (DP) Regulations, for the quarter ended March 31, 2026.6 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Procter & Gamble Health Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve Intimation of Board ....27 Mar 2026 · Board Meeting / Board Meeting
Intimation for closure of trading window27 Mar 2026 · Insider Trading / SAST / Closure of Trading Window
Dear Sir, Please find attached communication in respect of deduction of TDS on the amount of dividend income from declaration of interim dividend for the Financial year 2025-26.6 Feb 2026 · Company Update / General

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 45.0000	27 Aug 2026	27 Aug 2026	—
Interim Dividend - Rs. - 110.0000	12 Feb 2026	12 Feb 2026	—
Special Dividend - Rs. - 50.0000	12 Feb 2026	12 Feb 2026	—
Final Dividend - Rs. - 45.0000	22 Aug 2025	22 Aug 2025	—
Interim Dividend - Rs. - 80.0000	21 Feb 2025	21 Feb 2025	—
Final Dividend - Rs. - 60.0000	28 Nov 2024	—	—

Board meetings

2 Nov 2026 Board Meeting - Financial Results
6 Aug 2026 Board Meeting - Financial Results